Synopsys (SNPS) Expected to Post Quarterly Sales of $774.77 Million

Equities analysts expect Synopsys (NASDAQ:SNPS) to announce sales of $774.77 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Synopsys’ earnings, with the lowest sales estimate coming in at $767.50 million and the highest estimate coming in at $779.00 million. Synopsys reported sales of $680.07 million in the same quarter last year, which indicates a positive year-over-year growth rate of 13.9%. The business is scheduled to issue its next earnings report on Wednesday, May 16th.

On average, analysts expect that Synopsys will report full year sales of $774.77 million for the current financial year, with estimates ranging from $2.94 billion to $2.96 billion. For the next year, analysts anticipate that the company will post sales of $3.12 billion per share, with estimates ranging from $3.10 billion to $3.14 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Synopsys.

Synopsys (NASDAQ:SNPS) last issued its quarterly earnings data on Wednesday, February 21st. The semiconductor company reported $1.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.00 by $0.10. Synopsys had a return on equity of 6.72% and a net margin of 1.63%. The company had revenue of $769.40 million during the quarter, compared to analyst estimates of $750.43 million. During the same quarter in the previous year, the firm earned $0.94 earnings per share. Synopsys’s revenue was up 17.9% on a year-over-year basis.

Several analysts have issued reports on SNPS shares. JPMorgan Chase lowered Synopsys from a “neutral” rating to an “underweight” rating and set a $87.00 target price for the company. in a research note on Tuesday, December 12th. BidaskClub lowered Synopsys from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. KeyCorp reaffirmed an “overweight” rating and issued a $110.00 target price (up previously from $106.00) on shares of Synopsys in a research note on Thursday, February 22nd. Zacks Investment Research lowered Synopsys from a “hold” rating to a “strong sell” rating in a research note on Monday, February 26th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Synopsys in a research note on Friday, February 23rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $97.33.

SNPS traded down $1.57 during midday trading on Friday, hitting $81.39. The stock had a trading volume of 1,206,955 shares, compared to its average volume of 842,684. The firm has a market cap of $12,104.73, a P/E ratio of 92.49, a P/E/G ratio of 5.24 and a beta of 1.09. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.68 and a quick ratio of 0.68. Synopsys has a 1 year low of $70.55 and a 1 year high of $94.80.

In other news, EVP Joseph W. Logan sold 10,313 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $84.69, for a total transaction of $873,407.97. Following the completion of the sale, the executive vice president now owns 78,584 shares of the company’s stock, valued at $6,655,278.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, General Counsel John F. Runkel, Jr. sold 10,000 shares of the stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $87.00, for a total value of $870,000.00. Following the sale, the general counsel now directly owns 23,052 shares of the company’s stock, valued at approximately $2,005,524. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,245 shares of company stock valued at $2,529,005. Insiders own 1.84% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. First Trust Advisors LP raised its holdings in shares of Synopsys by 426.3% during the fourth quarter. First Trust Advisors LP now owns 1,038,634 shares of the semiconductor company’s stock valued at $88,533,000 after acquiring an additional 841,300 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Synopsys by 5.5% during the fourth quarter. BlackRock Inc. now owns 12,640,021 shares of the semiconductor company’s stock valued at $1,077,434,000 after acquiring an additional 658,966 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Synopsys by 37.5% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,853,499 shares of the semiconductor company’s stock valued at $157,992,000 after acquiring an additional 505,334 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of Synopsys during the fourth quarter valued at approximately $27,325,000. Finally, Carillon Tower Advisers Inc. bought a new position in shares of Synopsys during the fourth quarter valued at approximately $26,785,000. 90.54% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/09/synopsys-snps-expected-to-post-quarterly-sales-of-774-77-million.html.

About Synopsys

Synopsys, Inc provides electronic design automation (EDA) software products used to design and test integrated circuits (ICs). It offers Galaxy Design platform that offers IC design solutions; Verification Continuum Platform, which provides virtual prototyping, static and formal verification, simulation, emulation, field-programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions.

Get a free copy of the Zacks research report on Synopsys (SNPS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synopsys (NASDAQ:SNPS)

Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply